Last quarter (Q3 2023), Eledon Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Eledon Pharmaceuticals's net income was $-10.35M. See Eledon Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-
Operating Expense	$ -26.03M	$ 88.43M	$ 36.87M	$ 16.18M	$ 14.18M	$ 14.06M
Operating Income	$ -42.70M	$ -88.43M	$ -36.87M	$ -16.18M	$ -14.18M	$ -14.06M
Net Non Operating Interest Income Expense	-	-	-	$ -4.83M	$ 0.00	-
Other Income Expense	$ -2.27M	$ -462.00K	$ -7.00K	$ -2.20M	$ -1.83M	$ -5.00K
Pretax Income	$ -89.08M	$ -87.97M	$ -36.86M	$ -23.21M	$ -16.01M	$ -14.06M
Tax Provision	$ -114.00K	-	$ -2.35M	$ -404.00K	$ 0.00	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -89.08M	$ -87.97M	$ -34.51M	$ -22.81M	$ -16.01M	$ -14.06M
Basic EPS	$ -6.28	$ -6.16	$ -2.33	$ -15.72	$ -24.48	$ -28.08
Diluted EPS	$ -5.59	$ -6.16	$ -2.33	$ -15.72	$ -24.48	$ -28.08
Basic Average Shares	$ 82.55M	$ 14.29M	$ 14.82M	$ 1.45M	$ 655.53K	$ 500.30K
Diluted Average Shares	$ 82.55M	$ 14.29M	$ 14.82M	$ 1.45M	$ 655.53K	$ 500.30K
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ -26.03M	$ 88.43M	$ 36.87M	$ 16.18M	$ 14.18M	$ 14.06M
Net Income From Continuing And Discontinued Operation	$ -89.08M	$ -87.97M	$ -34.51M	$ -22.81M	$ -16.01M	$ -14.06M
Normalized Income	$ -15.74M	$ -20.85M	-	$ -20.57M	$ -14.14M	$ -14.06M
Interest Expense	-	-	-	-	-	-
EBIT	$ -89.08M	$ -87.97M	$ -36.86M	$ -16.18M	$ -14.18M	$ -14.06M
EBITDA	$ -78.46M	$ -87.59M	$ -36.66M	$ -16.00M	$ -14.00M	$ -14.05M

Currency in USD

Eledon Pharmaceuticals Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing